Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results For SGLT2 Inhibitor Remogliflozin Etabonate

RALEIGH, N.C., April 16, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) and BHV Pharma today announced positive results from two 12-week phase 2b clinical studies of remogliflozin etabonate in type 2 diabetics. The primary end point was HbA1c with secondary end points of fasting plasma glucose, serum lipids, body weight, safety and tolerability. Remogliflozin etabonate is a selective SGLT2 inhibitor indicated for type 2 diabetes and NASH. Islet Sciences will present the full results of the two phase 2b clinical studies at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17th.

Help employers find you! Check out all the jobs and post your resume.